A therapeutic drug strategy against colorectal cancer stem cells in mice is reported this week in Nature Medicine. As cancer stem cells are considered to be one of the reasons for the cause of therapy resistance and tumor relapse, this approach could be further developed for more effective cancer treatments.
Cancers are composed of various cell populations, including a small but recalcitrant stem cell fraction that can replenish itself and also give rise to more differentiated tumor cells. The elimination of the cancer stem cell population is considered necessary to achieve complete cancer eradication; however, these stem cells have unique properties that make them resistant to many cancer therapies, and so far they have proven to be elusive targets.
John Dick and colleagues identify a mouse protein BMI-1, a protein that can affect the expression of genes, as a crucial factor for stem cell self-renewal and tumor formation in human colorectal cell lines and colorectal tumor patient samples. The authors develop a compound that diminishes BMI-1 levels and therefore impairs cancer stem function and growth of primary human colorectal cancers in mice. These results suggest that BMI-1 inhibition could be used to improve cancer therapy and provide lasting anti-tumor effects.
Environment: Value of national parks’ impact on mental health estimatedNature Communications
Nature Reviews Endocrinology: A new approach for assessing health risks of endocrine disruptorsNature Reviews Endocrinology
Neuroscience: A brain-scanning bike helmetNature Communications